Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Organon & Co. Common Stock (NY:OGN)

9.760 +0.430 (+4.61%)
Official Closing Price Updated: 4:10 PM EDT, Apr 17, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 6,996,760
Open 9.250
Bid (Size) 9.650 (200)
Ask (Size) 9.750 (700)
Prev. Close 9.330
Today's Range 9.206 - 9.780
52wk Range 5.690 - 13.24
Shares Outstanding 259,965,579
Dividend Yield 0.82%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Organon’s VTAMA® (tapinarof) cream, 1%, Granted Strong Recommendation in the 2026 American Academy of Dermatology Guidelines for Pediatric Atopic Dermatitis
From Organon & Co.
Via Business Wire
News headline image
3 Reasons to Avoid OGN and 1 Stock to Buy Instead
Over the last six months, Organon’s shares have sunk to $9.03, producing a disappointing 5.9% loss - a stark contrast to the S&P 500’s 2.5% gain. This may ha... 
Via StockStory
Topics Stocks

Performance

YTD
+34.8%
+34.8%
1 Month
+52.7%
+52.7%
3 Month
+12.2%
+12.2%
6 Month
+4.1%
+4.1%
1 Year
-9.8%
-9.8%

More News

Read More
News headline image
Traders are paying attention to the gapping stocks in Friday's session. ↗
Via Chartmill
Topics Artificial Intelligence
Organon & Co (NYSE:OGN) Shares Drop on Q4 Earnings Miss and Flat 2026 Outlook ↗
Via Chartmill
Topics Earnings
News headline image
Discover the top movers in Friday's pre-market session. ↗
Via Chartmill
News headline image
Guardant Health, Organon, Fortrea, QuidelOrtho, and Charles River Laboratories Stocks Trade Down, What You Need To Know
Via StockStory
Topics Government Stocks
News headline image
Organon Debuts New Analysis of VTAMA® (tapinarof) cream, 1%, Phase 3 Pooled Data Demonstrating Early and Consistent Skin Clearance and Itch Improvement in Atopic Dermatitis Patients Down to 2 Years of Age
From Organon & Co.
Via Business Wire
News headline image
3 Cash-Producing Stocks We’re Skeptical Of
Via StockStory
Topics Fraud
News headline image
Does This $25 Million Bet on a Stock Down 61% Signal Turnaround Potential at $6? ↗
Via The Motley Fool
News headline image
3 Value Stocks We Approach with Caution
Via StockStory
News headline image
1 Stock Under $10 to Own for Decades and 2 That Underwhelm
Via StockStory
News headline image
3 of Wall Street’s Favorite Stocks We Approach with Caution
Via StockStory
News headline image
3 Small-Cap Stocks We Approach with Caution
Via StockStory
News headline image
New Analysis of Organon’s VTAMA® (tapinarof) cream, 1%, Phase 3 Data Showed Early and Consistent Improvement in Patient-Reported Sleep Subdomains in Pediatric Patients Down to 2 Years of Age with Atopic Dermatitis
From Organon & Co.
Via Business Wire
News headline image
The Pivot to Growth: Viatris (VTRS) Enters Phase 2 with 2026 Dividend and Capital Allocation Strategy
Via Finterra
Topics Economy
News headline image
Organon Enters into Agreement to License MIUDELLA®, Sebela Pharmaceuticals’ Hormone-Free Intrauterine Device
From Organon & Co.
Via Business Wire
News headline image
5 Revealing Analyst Questions From Organon’s Q4 Earnings Call
Via StockStory
Topics Earnings
News headline image
Amphastar Pharmaceuticals, Novavax, and Organon Shares Skyrocket, What You Need To Know
Via StockStory
Topics Economy
News headline image
OGN Q4 Deep Dive: Margin Compression and U.S. Headwinds Shape 2026 Outlook
Via StockStory
News headline image
Organon (OGN) Q4 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
Organon (NYSE:OGN) Reports Q4 CY2025 In Line With Expectations
Via StockStory
News headline image
Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2025
From Organon & Co.
Via Business Wire
News headline image
Organon Earnings: What To Look For From OGN
Via StockStory
Topics Artificial Intelligence World Trade
News headline image
2 Healthcare Stocks with Promising Prospects and 1 We Brush Off
Via StockStory
Topics Stocks
News headline image
Organon To Report Fourth Quarter and Full Year 2025 Results and Host Conference Call on February 12, 2026
From Organon & Co.
Via Business Wire

Frequently Asked Questions

Is Organon & Co. Common Stock publicly traded?
Yes, Organon & Co. Common Stock is publicly traded.
What exchange does Organon & Co. Common Stock trade on?
Organon & Co. Common Stock trades on the New York Stock Exchange
What is the ticker symbol for Organon & Co. Common Stock?
The ticker symbol for Organon & Co. Common Stock is OGN on the New York Stock Exchange
What is the current price of Organon & Co. Common Stock?
The current price of Organon & Co. Common Stock is 9.760
When was Organon & Co. Common Stock last traded?
The last trade of Organon & Co. Common Stock was at 04/17/26 04:10 PM ET
What is the market capitalization of Organon & Co. Common Stock?
The market capitalization of Organon & Co. Common Stock is 2.54B
How many shares of Organon & Co. Common Stock are outstanding?
Organon & Co. Common Stock has 3B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.